{"id":31260,"date":"2022-11-29T14:25:28","date_gmt":"2022-11-29T17:25:28","guid":{"rendered":"https:\/\/med.estrategia.com\/portal\/entidade\/tocilizumabe\/"},"modified":"2022-12-01T09:55:09","modified_gmt":"2022-12-01T12:55:09","slug":"tocilizumabe","status":"publish","type":"entity","link":"https:\/\/med.estrategia.com\/portal\/entidade\/tocilizumabe\/","title":{"rendered":"Tocilizumabe"},"content":{"rendered":"<p>O tocilizumabe &eacute; um anticorpo monoclonal que bloqueia a a&ccedil;&atilde;o da interleucina-6 (IL-6) e que faz parte das novas drogas anti-reum&aacute;ticas modificadoras da doen&ccedil;a (DMARD). A IL-6 est&aacute; implicada na patog&ecirc;nese de v&aacute;rias doen&ccedil;as, incluindo doen&ccedil;as inflamat&oacute;rias, osteoporose e neoplasia.<p>No entanto, nos &uacute;ltimos anos esta droga ganhou import&acirc;ncia no cen&aacute;rio mundial ap&oacute;s alguns estudos demonstrarem redu&ccedil;&atilde;o na mortalidade em pacientes graves com COVID-19.<\/p><\/p>\n","protected":false},"excerpt":{"rendered":"O tocilizumabe &eacute; um anticorpo monoclonal que bloqueia a a&ccedil;&atilde;o da interleucina-6 (IL-6) e que faz parte das&hellip;\n","protected":false},"author":33,"featured_media":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"wl_entities_gutenberg":"","footnotes":""},"categories":[],"wl_entity_type":[191],"class_list":{"0":"post-31260","1":"entity","2":"type-entity","3":"status-publish","5":"wl_entity_type-thing"},"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v26.6 (Yoast SEO v26.6) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Tocilizumabe - Estrat\u00e9gia MED<\/title>\n<meta name=\"description\" content=\"O tocilizumabe \u00e9 um anticorpo monoclonal que bloqueia a a\u00e7\u00e3o da interleucina-6 (IL-6) e que faz parte das novas drogas anti-reum\u00e1ticas...\" \/>\n<meta name=\"robots\" content=\"noindex, follow\" \/>\n<meta property=\"og:locale\" content=\"pt_BR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Tocilizumabe\" \/>\n<meta property=\"og:description\" content=\"O tocilizumabe \u00e9 um anticorpo monoclonal que bloqueia a a\u00e7\u00e3o da interleucina-6 (IL-6) e que faz parte das novas drogas anti-reum\u00e1ticas...\" \/>\n<meta property=\"og:url\" content=\"https:\/\/med.estrategia.com\/portal\/entidade\/tocilizumabe\/\" \/>\n<meta property=\"og:site_name\" content=\"Estrat\u00e9gia MED\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/estrategiamed1\" \/>\n<meta property=\"article:modified_time\" content=\"2022-12-01T12:55:09+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/med.estrategia.com\/portal\/wp-content\/uploads\/2021\/12\/2ba766a1.png\" \/>\n\t<meta property=\"og:image:width\" content=\"1020\" \/>\n\t<meta property=\"og:image:height\" content=\"680\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@estrategiamed_\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\/\/med.estrategia.com\/portal\/entidade\/tocilizumabe\/\",\"url\":\"https:\/\/med.estrategia.com\/portal\/entidade\/tocilizumabe\/\",\"name\":\"Tocilizumabe - Estrat\u00e9gia MED\",\"isPartOf\":{\"@id\":\"https:\/\/med.estrategia.com\/portal\/#website\"},\"datePublished\":\"2022-11-29T17:25:28+00:00\",\"dateModified\":\"2022-12-01T12:55:09+00:00\",\"description\":\"O tocilizumabe \u00e9 um anticorpo monoclonal que bloqueia a a\u00e7\u00e3o da interleucina-6 (IL-6) e que faz parte das novas drogas anti-reum\u00e1ticas...\",\"breadcrumb\":{\"@id\":\"https:\/\/med.estrategia.com\/portal\/entidade\/tocilizumabe\/#breadcrumb\"},\"inLanguage\":\"pt-BR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/med.estrategia.com\/portal\/entidade\/tocilizumabe\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/med.estrategia.com\/portal\/entidade\/tocilizumabe\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/med.estrategia.com\/portal\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Tocilizumabe\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/med.estrategia.com\/portal\/#website\",\"url\":\"https:\/\/med.estrategia.com\/portal\/\",\"name\":\"Estrat\u00e9gia MED\",\"description\":\"\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/med.estrategia.com\/portal\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"pt-BR\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Tocilizumabe - Estrat\u00e9gia MED","description":"O tocilizumabe \u00e9 um anticorpo monoclonal que bloqueia a a\u00e7\u00e3o da interleucina-6 (IL-6) e que faz parte das novas drogas anti-reum\u00e1ticas...","robots":{"index":"noindex","follow":"follow"},"og_locale":"pt_BR","og_type":"article","og_title":"Tocilizumabe","og_description":"O tocilizumabe \u00e9 um anticorpo monoclonal que bloqueia a a\u00e7\u00e3o da interleucina-6 (IL-6) e que faz parte das novas drogas anti-reum\u00e1ticas...","og_url":"https:\/\/med.estrategia.com\/portal\/entidade\/tocilizumabe\/","og_site_name":"Estrat\u00e9gia MED","article_publisher":"https:\/\/www.facebook.com\/estrategiamed1","article_modified_time":"2022-12-01T12:55:09+00:00","og_image":[{"width":1020,"height":680,"url":"https:\/\/med.estrategia.com\/portal\/wp-content\/uploads\/2021\/12\/2ba766a1.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_site":"@estrategiamed_","schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/med.estrategia.com\/portal\/entidade\/tocilizumabe\/","url":"https:\/\/med.estrategia.com\/portal\/entidade\/tocilizumabe\/","name":"Tocilizumabe - Estrat\u00e9gia MED","isPartOf":{"@id":"https:\/\/med.estrategia.com\/portal\/#website"},"datePublished":"2022-11-29T17:25:28+00:00","dateModified":"2022-12-01T12:55:09+00:00","description":"O tocilizumabe \u00e9 um anticorpo monoclonal que bloqueia a a\u00e7\u00e3o da interleucina-6 (IL-6) e que faz parte das novas drogas anti-reum\u00e1ticas...","breadcrumb":{"@id":"https:\/\/med.estrategia.com\/portal\/entidade\/tocilizumabe\/#breadcrumb"},"inLanguage":"pt-BR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/med.estrategia.com\/portal\/entidade\/tocilizumabe\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/med.estrategia.com\/portal\/entidade\/tocilizumabe\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/med.estrategia.com\/portal\/"},{"@type":"ListItem","position":2,"name":"Tocilizumabe"}]},{"@type":"WebSite","@id":"https:\/\/med.estrategia.com\/portal\/#website","url":"https:\/\/med.estrategia.com\/portal\/","name":"Estrat\u00e9gia MED","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/med.estrategia.com\/portal\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"pt-BR"}]}},"_wl_alt_label":[],"wl:entity_url":"\/entity\/tocilizumabe","_links":{"self":[{"href":"https:\/\/med.estrategia.com\/portal\/wp-json\/wp\/v2\/entities\/31260","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/med.estrategia.com\/portal\/wp-json\/wp\/v2\/entities"}],"about":[{"href":"https:\/\/med.estrategia.com\/portal\/wp-json\/wp\/v2\/types\/entity"}],"author":[{"embeddable":true,"href":"https:\/\/med.estrategia.com\/portal\/wp-json\/wp\/v2\/users\/33"}],"replies":[{"embeddable":true,"href":"https:\/\/med.estrategia.com\/portal\/wp-json\/wp\/v2\/comments?post=31260"}],"version-history":[{"count":2,"href":"https:\/\/med.estrategia.com\/portal\/wp-json\/wp\/v2\/entities\/31260\/revisions"}],"predecessor-version":[{"id":31375,"href":"https:\/\/med.estrategia.com\/portal\/wp-json\/wp\/v2\/entities\/31260\/revisions\/31375"}],"wp:attachment":[{"href":"https:\/\/med.estrategia.com\/portal\/wp-json\/wp\/v2\/media?parent=31260"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/med.estrategia.com\/portal\/wp-json\/wp\/v2\/categories?post=31260"},{"taxonomy":"wl_entity_type","embeddable":true,"href":"https:\/\/med.estrategia.com\/portal\/wp-json\/wp\/v2\/wl_entity_type?post=31260"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}